-

HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On July 29, 2026, the Federal Trade Commission (the “FTC”) filed a lawsuit against Hims, accusing the Company of sharing customers’ medical information with third-party advertisers. The FTC complaint accuses the Company of “deceptive and unlawful privacy practices,” including sharing sensitive details about patients’ health with Meta Platforms. On this news, Hims’s stock price fell $4.32 per share, or 14.73%, to close at $25.00 on July 29, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Hims securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

NYSE:HIMS

Release Versions
$Cashtags

Contacts

More News From Kirby McInerney LLP

GILAT SATELLITE NETWORKS LTD. INVESTIGATION: GILT Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Gilat Satellite Networks Ltd. (“Gilat” or the “Company”) (NASDAQ: GILT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Gilat securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp....

BRIGHT MINDS BIOSCIENCES DRUG INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 52.3% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 2, 2026, Bright Minds announced that the FDA had notified the Company that it...

MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 3, 2026, Madrigal disclosed in its quarterly report on Form 10-Q that, on Oc...
Back to Newsroom